KRAS(G12C) His Tag Protein, Human

K-Ras 2,Ki-Ras,c-K-ras,c-Ki-ras,GTPase KRas,KRAS2,RASK2

Datasheet COA

价格￥1,490.00 （供应商现货： 3-5个工作日）

货号 UA085047

规格

10μg50μg100μg500μg

数量

产品介绍

产品介绍评论(0)

产品规格

物种

Human
分子别名

K-Ras 2, Ki-Ras, c-K-ras, c-Ki-ras, GTPase KRas, KRAS2, RASK2
Accession

P01116-2
表达序列

Thr2-Cys185(G12C) with His Tag at the C-Terminus
表达宿主

E.coli
分子量

20-25kDa (Reducing)
纯度

＞95% by SDS-PAGE
活性

The specific activity of KRAS(G12C) was determined to be＞ 400 pmol/min/mg in a GTPase-Glo assay using GTP solution substrate.
标记

Unconjugated
标签

His Tag
性状

Liquid
缓冲体系

50mM Tris, 200mM NaCl, 20% Glycerol, 1mM DTT, pH7.5
储存条件

Stable for 12 months upon stored at -80℃ from the date of receipt. And avoid repeated freeze-thaws cycles.
文献引用

1.Kim D, Xue JY, Lito P. Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients. Cell. 2020 Nov 12;183(4):850-859.
2.Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, Gaida K, Holt T, Knutson CG, Koppada N, Lanman BA, Werner J, Rapaport AS, San Miguel T, Ortiz R, Osgood T, Sun JR, Zhu X, McCarter JD, Volak LP, Houk BE, Fakih MG, O'Neil BH, Price TJ, Falchook GS, Desai J, Kuo J, Govindan R, Hong DS, Ouyang W, Henary H, Arvedson T, Cee VJ, Lipford JR. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019 Nov;575(7781):217-223.

背景介绍

KRAS(G12C) is an oncogenic mutant of the RAS family member KRAS, in which a glycine at position 12 is mutated to cysteine. This mutation disrupts GTP hydrolysis, causing the protein to remain persistently in the GTP-bound "activated state". The G12C mutation introduces a nucleophilic cysteine into the Switch II pocket, providing a binding site for covalent inhibitors (e.g., Sotorasib, Adagrasib), which lock KRAS in the inactive GDP-bound conformation. This mutation constitutively activates downstream pathways such as RAF-MEK-ERK and PI3K-AKT, driving cell proliferation and survival, making it a key driver in non-small cell lung cancer (NSCLC; ~14%), pancreatic cancer (~2%), and colorectal cancer (~3%). Clinically, KRAS(G12C) was once considered an "undruggable" target until the first covalent inhibitor, AMG 510, emerged in 2019, marking a major breakthrough in precision oncology. To date, the FDA has approved Sotorasib and Adagrasib for second-line treatment of KRAS G12C-mutant NSCLC. Combination therapy with EGFR inhibitors has also shown significant efficacy in colorectal cancer; however, acquired resistance remains a clinical challenge.

操作步骤

实验方法
实验原理：GTPase Glo™ 检测法通过检测KRAS反应中GTP水解后剩余的GTP量来评估KRAS活性。
实验材料
1.KRAS(G12C) His Tag Protein, Human
2.GTPase Glo™ Assay (Promega, Catalog # V7681T)
3.Solid white multi-well plate (384-well plate) (Corning, Catalog #3572)
4.Plate Reader (PerkinElmer)
实验步骤
1.使用GTPase/GAP Buffer配制包含10 µM GTP和2 mM DTT 的2X GTP溶液。
2.将KRAS用GTPase/GAP Buffer稀释至100 µg/mL、80 µg/mL和60 µg/mL，然后分别向384孔板的每个孔中加入5 µL。
3.向每个孔中加入5 µL步骤1中配制的2X GTP溶液以启动反应。使用5 µL GTPase/GAP Buffer与2X GTP溶液作为空白对照。反应总体积为10 µL。
4.室温（22-25℃）下孵育反应30分钟。
5.轻轻颠倒混匀解冻后的GTPase Glo™ Reagent, 500X，请勿涡旋振荡。根据需要，按比例增减下述成分的体积，配制所需体积的复溶GTPase Glo™。
Sample Name
Amount
GTPase Glo ™ Reagent, 500X
2 μL
ADP, 10 mM
0.5 μL
GTPase Glo ™ Buffer
998 μL
Total volume
1 mL

6.向完成反应的反应体系中加入10 µL复溶后的GTPase-Glo™ Reagent，短暂混匀后，在室温（22–25°C）下震荡孵育30分钟。
7.加入20 µL检测试剂，将酶标板在室温（22–25°C）下孵育5–10分钟。
8.分别在发射波长555 nm（luminescence）下以终点模式读数。
9.计算比活性。
Specific Activity (pmol/min/μg) =
(1-Sample OD / BLANK OD)*50pmol
Incubation time(min) ×amount of enzyme (μg)

样品OD值：剩余ATP的OD值
空白OD值：添加GTP的OD值
50 pmol：添加的GTP量
孵育时间：30分钟
酶量：0.5 μg、0.4 μg和0.3 μg

生物活性
- The specific activity of KRAS(G12C) was determined to be＞ 400 pmol/min/mg in a GTPase-Glo assay using GTP solution substrate.
电泳
- 1μg (R: reducing condition, N:non-reducing condition).